Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial
Primary result · TIRResult — go to the resultIncrease in TIR 17 min/day 95% CrI −105 to +153Authors' conclusion
Compared with SMBG, isCGM in T2D individuals with MI marginally increases TIR and significantly reduces hypoglycemic exposure while equally improving HbA1c, explaining its cost effectiveness. Studies are required to understand whether these glycemic differences translate into longer-term clinical benefit.
Study context
- Population
- Individuals with T2D and recent myocardial infarction (MI), treated with insulin and/or a sulphonylurea before hospital admission; median age 63 years, 73% menrandomly assigned
- Participants
- 141 individuals
- Comparison
- Intermittently scanned continuous glucose monitoring (isCGM) vs self-monitoring of blood glucose (SMBG)
- Primary endpoint
- TIR (glucose 3.9-10 mmol/L/day)
- Follow-up
- Days 76-90 post-randomization
Methodological detailsmulticenter, two-arm
- Multicenter
- Two-arm
Primary result
TIR · days 76-90
Increase in time in range (TIR)
17 min/day
95% CrI −105 to +153
isCGMvs SMBG
increase in TIR 17 min/day (95% CrI −105 to +153)
As reported in the abstract
Further findings
| Outcome | Difference (min/day) (95% CI) | |
|---|---|---|
| Hypoglycemic exposure (<3.9 mmol/L) · days 76-90 | −80 (−118 to −43) | |
| Hypoglycemic exposure (<3.9 mmol/L) · days 16-30 | −28 (−92 to 2) | |
| −150−100−50050Difference, min/day (linear scale) |
Hemoglobin A1c (HbA1c) change from baseline · 3 months
- Similar HbA1c reductions in both arms
- 7 mmol/mol
Quality of life (QOL) and cost effectiveness
- QOL measures marginally favored isCGM; the intervention proved cost effective
Safety
Events
| Outcome | isCGM | SMBG |
|---|---|---|
| Combined glycemic emergencies and mortality | 4 | 7 |
Original publication
Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial. Diabetes Care. Published 14 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →